United States - English - NLM (National Library of Medicine)

burel pharmaceuticals, llc - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: • who have the hla-b*5701 allele [see warnings and precautions (5.1)]. • with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. • with moderate or severe hepatic impairment [see use in specific populations (8.7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atl

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

aurobindo pharma limited, india - abacavir sulfate 60mg , lamivudine 30 mg tablets - tablets - 60 + 30 mg

United States - English - NLM (National Library of Medicine)

laurus labs limited - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: - who have the hla-b*5701 allele [see warnings and precautions (5.1)] . - with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. - with moderate or severe hepatic impairment [see use in specific populations (8.7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta

Kenya - English - Pharmacy and Poisons Board

aurobindo pharma limited plot no. 11, survey 9, hitech city, hyderabad - abacavir sulfate usp - oral solution - abacavir sulfate 20 mg/ml - antivirals for systemic use:

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.78 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; silicified microcrystalline cellulose; purified talc; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - abacavir/lamivudine viatris tablets are a combination of two nucleoside analogues (abacavir and lamivudine). abacavir/lamivudine viatris is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - abacavir hydrochloride monohydrate,lamivudine -

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 150 mg; abacavir sulfate, quantity: 351 mg (equivalent: abacavir, qty 300 mg); zidovudine, quantity: 300 mg - tablet, film coated - excipient ingredients: purified water; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; titanium dioxide; hypromellose; indigo carmine; iron oxide yellow; macrogol 400 - trizivir is indicated in antiretroviral therapy for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents over the age of 12 years. trizivir should not be administered to adults and adolescents who weigh less than 40kg because it is a fixed dose tablet, and the dose cannot be adjusted for this patient population.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

lupin limited, india - abacavir sulfate , lamivudine - tablet, dispersible - 120/60

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

lupin limited, india - abacavir sulfate , lamivudine - dispersible tablets - 120/60

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - abacavir sulfate -